Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Recent advances in microsystems technology and cell culture techniques have led to the development of organ-on-chip microdevices that produce tissue-level functionality, not possible with conventional culture models, by recapitulating natural tissue architecture and microenvironmental cues within microfluidic devices. Since the physiological microenvironments in living systems are mostly microfluidic in nature, the use of microfluidic devices facilitates engineering cellular microenvironments; the microfluidic devices allow for control of local chemical gradients and dynamic mechanical forces, which play important roles in cellular viability and function. The organ-on-chip microdevices have great potential to promote drug discovery and development, to model human physiology and disease, and to replace animal models for efficacy and toxicity testing. Recently, induced pluripotent stem (iPS) cells have been leveraged to develop organs-on-chips, which enable various types of organ models and disease models not possible with primary cells and cell lines. This Special Issue seeks to showcase research papers, short communications, and review articles that focus on: (1) microdevices to mimic or control cellular microenvironment; (2) microdevices to evaluate interactions between different organ models; (3) microdevices to maintain iPS cells or iPSC-derived cells; and (4) sensors and techniques to evaluate drug efficacy or toxicity.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Recent advances in microsystems technology and cell culture techniques have led to the development of organ-on-chip microdevices that produce tissue-level functionality, not possible with conventional culture models, by recapitulating natural tissue architecture and microenvironmental cues within microfluidic devices. Since the physiological microenvironments in living systems are mostly microfluidic in nature, the use of microfluidic devices facilitates engineering cellular microenvironments; the microfluidic devices allow for control of local chemical gradients and dynamic mechanical forces, which play important roles in cellular viability and function. The organ-on-chip microdevices have great potential to promote drug discovery and development, to model human physiology and disease, and to replace animal models for efficacy and toxicity testing. Recently, induced pluripotent stem (iPS) cells have been leveraged to develop organs-on-chips, which enable various types of organ models and disease models not possible with primary cells and cell lines. This Special Issue seeks to showcase research papers, short communications, and review articles that focus on: (1) microdevices to mimic or control cellular microenvironment; (2) microdevices to evaluate interactions between different organ models; (3) microdevices to maintain iPS cells or iPSC-derived cells; and (4) sensors and techniques to evaluate drug efficacy or toxicity.